GH secretion in healthy adults is not random. Roughly 70–80% of the daily GH output occurs in a single large pulse tied to the first slow-wave sleep episode of the night — stage N3, characterised on EEG by high-amplitude, low-frequency delta waves. The hypothalamic neuropeptide driving that pulse is growth-hormone-releasing hormone (GHRH). Tesamorelin is a trans-3-hexenoyl modification of GHRH 1-44: structurally identical to endogenous GHRH at the receptor, but protected from dipeptidyl peptidase-IV (DPP-IV) cleavage so it stays active long enough to matter. That is why investigators interested in sleep architecture research increasingly reach for GHRH analogs — and why teams looking to buy tesamorelin UAE are contacting REVIVE LAB UAE for HPLC-tested supply.
Understanding why tesamorelin is relevant to slow-wave sleep research requires a short detour into the hypothalamic-pituitary circuit. GHRH neurons in the arcuate nucleus project to the median eminence and, through a separate collateral pathway, to sleep-promoting GABAergic interneurons in the preoptic area. The two outputs — GH pulse and SWS initiation — are not coincidentally co-timed; they share upstream circuitry. When investigators administer a GHRH agonist, they are not simply raising GH; they are engaging a network node that participates in delta-wave generation.
The practical implication for research is significant. Age-related GH decline — partly a consequence of reduced GHRH tone — correlates with reduced SWS in the same time-course. GHRH analogs such as tesamorelin provide researchers with a pharmacological handle to probe whether restoring GHRH receptor drive can influence sleep architecture in models of GH insufficiency. The clinical evidence base for tesamorelin's GH effects is now substantial, anchored by the Falutz and Stanley trial programmes reviewed below.
The sleep-architecture hypothesis for GHRH analogs rests on one foundational question: does the compound actually engage the GHRH receptor robustly enough to influence the GH-sleep axis? The Falutz and Stanley trial programmes answer that question with high-quality phase-III data, even though those trials were designed around lipodystrophy and hepatic endpoints rather than polysomnography.
The pivotal New England Journal of Medicine paper enrolled 412 HIV-positive patients with excess visceral adiposity and randomised them to tesamorelin 2 mg/day subcutaneous versus placebo. After 26 weeks, visceral adipose tissue (VAT) fell by 15–18% in the treatment group versus placebo, with a parallel rise in IGF-1 of approximately 50%. That IGF-1 signal is the key data point for sleep researchers: a 50% increase in the GH-surrogate biomarker from a 2 mg/day dose confirms that tesamorelin achieves meaningful GHRH receptor engagement in vivo — the same magnitude of engagement that, in basic research models, is associated with delta-wave promotion during sleep.
The 2010 extension study followed the original cohort through an additional 26 weeks of tesamorelin at the same 2 mg/day research-context dosing. VAT reductions were maintained and, critically, the IGF-1 elevation was sustained — ruling out rapid receptor desensitisation. For investigators designing chronic sleep-architecture studies with GHRH analogs, the durability of receptor engagement through this extension period is operationally important: it suggests that longitudinal polysomnography protocols using tesamorelin would not face a tolerance confound within standard study durations.
Stanley and colleagues at Massachusetts General Hospital extended tesamorelin research into HIV-associated non-alcoholic fatty liver disease. The 2014 JAMA trial demonstrated a 32% reduction in liver fat versus placebo; the 2019 Lancet HIV 12-month follow-on confirmed durable hepatic benefit. These trials reinforce the consistent metabolic signature of tesamorelin's GHRH agonism — including sustained IGF-1 elevation — and demonstrate that the compound's GH-axis engagement is robust across diverse subject populations and study durations. Investigators studying SWS can draw on this safety and tolerability dataset when designing their own research protocols.
| Trial | N | Duration | Dose | Key GH-Axis Finding |
|---|---|---|---|---|
| Falutz et al. 2007 NEJM | 412 | 26 weeks | 2 mg/day SC | IGF-1 +~50%; VAT -15-18% |
| Falutz et al. 2010 extension | Subset | +26 weeks | 2 mg/day SC | Sustained IGF-1; no tolerance signal |
| Stanley et al. 2014 JAMA | HIV-NAFLD cohort | 6 months | 2 mg/day SC | Liver fat -32%; IGF-1 maintained |
| Stanley et al. 2019 Lancet HIV | HIV-NAFLD cohort | 12 months | 2 mg/day SC | Durable hepatic & GH-axis engagement |
For researchers designing a GHRH-SWS protocol using tesamorelin, several practical parameters emerge directly from the published trial data and the known pharmacology of the compound.
The Falutz and Stanley trials both used 2 mg/day SC as the reference dose. Some investigators begin at 1 mg/day — particularly in protocols where the research question concerns dose-response relationships in GH-sleep coupling. REVIVE LAB UAE stocks tesamorelin in 5 mg and 10 mg vials, the two formats that accommodate both dosing tiers with straightforward reconstitution arithmetic. No other vial strengths are stocked; investigators should not expect or request 1 mg or 2 mg presentation — the 5 mg and 10 mg vials cover all research-use dosing scenarios.
Tesamorelin is supplied as a lyophilised powder. Reconstitution with bacteriostatic water (BAC water) at the bench gives a stable solution maintained at 2–8°C for the manufacturer-specified window. For sleep-architecture studies requiring repeated sampling across polysomnography nights, investigators typically reconstitute fresh each week to stay well within stability margins. The table below covers the most common reconstitution scenarios for the two stocked vial sizes.
| Vial | BAC Water Added | Concentration | Volume per 1 mg Research Dose |
|---|---|---|---|
| Tesamorelin 5 mg | 2.5 mL | 2 mg/mL | 0.5 mL |
| Tesamorelin 5 mg | 1 mL | 5 mg/mL | 0.2 mL |
| Tesamorelin 10 mg | 5 mL | 2 mg/mL | 0.5 mL |
| Tesamorelin 10 mg | 2 mL | 5 mg/mL | 0.2 mL |
Because the dominant GH pulse is coupled to sleep onset, investigators studying SWS-GH architecture typically administer the GHRH analog 30–60 minutes prior to lights-out in the research context. This timing aligns the pharmacokinetic peak with the physiological window for GHRH-driven GH secretion. Tesamorelin's extended half-life relative to endogenous GHRH — a consequence of the trans-3-hexenoyl N-terminal modification — makes this pre-sleep window pharmacologically tractable in a way that shorter GHRH fragments are not.
The quality ceiling in GHRH-SWS research is only as high as the compound you put in the protocol. An HPLC purity shortfall at the vial level introduces a dosing uncertainty that no statistical analysis plan can correct for. REVIVE LAB UAE supplies tesamorelin 5 mg and 10 mg with third-party HPLC verification at ≥99% purity, lot-specific certificate of analysis (COA) available on request, and cold-chain insulation validated for UAE summer conditions. That is the operational standard the Falutz and Stanley teams ran on — and it is the standard investigators who buy tesamorelin UAE from REVIVE LAB UAE should expect as the baseline, not an upsell.
REVIVE LAB UAE is a Dubai-based peptides UAE supplier. Not a freight-forwarder relabelling offshore stock. Every batch is sourced, tested, and dispatched from within the UAE — which is why same-day delivery in Dubai is possible, and why tesamorelin Dubai 24h delivery is the standard rather than an aspirational claim. Cash on delivery is available across all 7 emirates. Packaging is plain, unbranded outer cartons by default.
| Emirate / Key Districts | Delivery Window | Cash on Delivery | Cold-Chain Packaging |
|---|---|---|---|
| Dubai (Marina, JBR, DIFC, Business Bay, JVC, Downtown, Palm, Jumeirah, Emirates Hills) | Same-day, 4-8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas Island, Saadiyat, Reem Island) | Next-day, 18-24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8-18 hours | Yes | Yes |
| Ajman | Next-day, 18-24 hours | Yes | Yes |
| Ras Al Khaimah (RAK) | Next-day, 18-24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain (UAQ) | Next-day, 18-24 hours | Yes | Yes |
| Al Ain | Next-day, 24 hours | Yes | Yes |
A research team in Dubai Marina that orders tesamorelin in stock UAE before the daily cut-off typically receives cold-chain vials within the same afternoon. That turnaround matters operationally: sleep-architecture research runs on night-by-night scheduling, and a 24-48 hour supply gap can stall a protocol. REVIVE LAB UAE's tesamorelin same day Dubai dispatch is specifically designed to eliminate that bottleneck for researchers across the UAE.
Yes. REVIVE LAB UAE supplies HPLC-verified tesamorelin 5 mg and 10 mg vials, lot-COA included, cold-chain dispatched across all 7 emirates. Orders placed before the daily cut-off receive same-day delivery within Dubai and tesamorelin 24h delivery to Abu Dhabi, Sharjah, RAK, Fujairah, Ajman, UAQ and Al Ain. Cash on delivery Dubai is available UAE-wide. All shipments are framed as research-use only and arrive in plain, unbranded packaging. Visit /buy-tesamorelin-uae/ to order.
REVIVE LAB UAE stocks tesamorelin 5 mg and 10 mg vials — the two formats used across the Falutz and Stanley published research programmes. Investigators in those trials referenced 2 mg/day subcutaneous dosing; some newer protocols explore 1 mg/day for dose-response work. No other vial strengths are stocked or required. Reconstitute with bacteriostatic water; store at 2-8°C and use within manufacturer stability windows.
Yes. Tesamorelin same day Dubai delivery covers all major Dubai districts — Marina, JBR, Business Bay, JVC, DIFC, Palm Jumeirah, Downtown and Jumeirah — for orders placed before the daily dispatch cut-off. Cash on delivery is supported across all seven emirates. All vials are HPLC-tested (≥99% purity), lot-COA verified, and cold-chain dispatched in insulated packaging rated for UAE summer conditions. For researchers outside Dubai, tesamorelin in stock UAE is dispatched next-day to every other emirate.